+0.470 (+1566.67%)
Range 0.260 - 0.510   (96.15%)
Open 0.510
Previous Close 0.030
Buy Price 0.357
Buy Volume -
Sell Price 0.361
Sell Volume -
Volume 5,935
Value -
Measurement Type Value
EPS (USD) -1.394
Trailing EPS (USD) -1.298
NAV (USD) -0.185
Cash In Hand (USD) 0.115
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV -0.286
Price / Cash In Hand 0.463
Issued & Paid-up Shares 41,928,000
Treasury Shares -
Market Cap (M) 0.84
Par Value (USD) n.a.
Beta - 75 Days 4.773
R-Squared - 75 Days(%) 2.09
Beta - 500 Days -6.781
R-Squared - 500 Days(%) 0.02
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 17 Sep 2020 05:20.
Data powered by
View All Events


ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�s products include ICT-107, ICT-140, ICT-121, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�s immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

Top Contributors

USNews avatar
Followers 218
Posts 1283333
SeekingAlphaRSS avatar
Followers 255
Posts 64148

Loading Chart...